Aug 4, 2026
Pharma organizations are generating more clinical and
scientific evidence than ever, yet the path from that evidence to a
confident strategic call hasn't kept up.
In this episode, Nabil Khan, Medical Director for Internal
Medicine Antivirals at Pfizer, digs into where AI genuinely helps
medical affairs and clinical teams move faster from raw data to
decisions, in conversation with host Yolandi de Weerdt. He lays out
the risk of treating AI output as fact rather than a starting
point, why training is the piece organizations most often
shortchange, and what it realistically takes to build a foundation
AI can be trusted to work from.
Emerj works with a select group of AI vendors to reach Fortune
500 decision makers through research, media, and direct access. If
you want to be considered, download our media kit at emerj.com/AD1